Corrigendum to "A beam-walking apparatus to assess behavioural impairments in MPTP-treated mice: Pharmacological validation with R-(-)-deprenyl" [J. Neurosci. Methods 164 (2007) 43-49] (DOI:10.1016/j.jneumeth.2007.03.021);A beam-walking apparatus to assess behavioural impairments in MPTP-treated mice: Pharmacological validation with R-(-)-deprenyl

Journal of Neuroscience Methods

Volumn 164, Issue 1, 2007, Pages 43-49

  Quinn, Leann P ^a   Perren, Marion J ^a   Brackenborough, Kim T ^a   Woodhams, Peter L ^a   Vidgeon Hart, Martin ^a   Chapman, Helen ^a   Pangalos, Menelas N ^b   Upton, Neil ^a   Virley, David J ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b PFIZER INC   (United States)

Author keywords

Beam walking apparatus; Dopamine; Mice; MPTP; R ( ) Deprenyl; Striatum; Substantia nigra; Tyrosine hydroxylase

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE; MONOAMINE OXIDASE B INHIBITOR; SELEGILINE; SODIUM CHLORIDE; TYROSINE 3 MONOOXYGENASE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; APPARATUS; ARTICLE; BEHAVIOR DISORDER; BRAIN DAMAGE; CONTROLLED STUDY; DOPAMINE BRAIN LEVEL; DOPAMINERGIC ACTIVITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOREACTIVITY; MALE; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; MOUSE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; STRIATE CORTEX; SUBSTANTIA NIGRA; TASK PERFORMANCE;

EID: 34250632043     PISSN: 01650270     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneumeth.2007.07.001     Document Type: Erratum

References (38)

1. Agid Y. Parkinson's disease: pathophysiology. Lancet 337 (1991) 1321-1323
2. Arai N., Misugi K., Goshima Y., and Misu Y. Evaluation of a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated C57 black mouse model of Parkinsonism. Brain Res 515 (1990) 57-63
3. Berardelli A., Rothwell J.C., Thompson P.D., and Hallett M. Pathophysiology of bradykinesia in Parkinson's disease. Brain 124 (2001) 2131-2146
4. Bernheimer H., Birkmayer W., Hornykiewicz O., Jellinger K., and Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington: clinical, morphological and neurochemical correlations. J. Neurol. Sci. 20 (1973) 415-455
5. Bezard E., and Gross C.E. Compensatory mechanisms in experimental and human parkinsonism: towards a dynamic approach. Prog. Neurobiol. 55 (1998) 93-116
6. Carter R.J., Lione L.A., Humby T., Mangiarini L., Mahal A., Bates G.P., et al. Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation. J Neurosci 19 8 (1999) 3248-3257
7. Chia L.G., Ni D.R., Cheng L., Kuo J.S., Cheng F.C., and Dryhurst G. Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 5,7-dihydroxytryptamine on the locomotor activity and striatal amines in C57BL/6 mice. Neurosci Lett 218 (1996) 67-71
8. Di Chiara G., Porceddu M.L., Vargiu L., Argiolas A., and Gessa G.L. Evidence of dopamine receptors mediating sedation in the mouse brain. Nature 264 (1976) 564-567
9. Dluzen D.E., Gao X., Story G.M., Anderson L.I., Kucera J., and Walro J.M. Evaluation of nigrostriatal dopaminergic function in adult +/+ and +/- BDNF mutant mice. Exp Neurol 170 (2001) 121-128
10. Drucker-Colin R., and Garcia-Hernandez F. A new motor test sensitive to aging and dopaminergic function. J Neurosci Meth 39 (1991) 153-161
11. Fernagut P.O., Diguet E., Labattu B., and Tison F. A simple method to measure stride length as an index of nigro-striatal dysfunction in mice. J Neurosci Meth 113 (2002) 123-130
12. Franklin K.B.J., and Paxinos G. The mouse brain in stereotaxic coordinates (1997), Academic press, San Diego
13. Fredriksson A., and Archer T. MPTP-induced behavioural and biochemical deficits: a parametric analysis. J Neural Transm 7 (1994) 123-132
14. Fredriksson A., Eriksson P., and Archer T. MPTP-induced deficits in motor activity: neuroprotective effects of the spintrapping agent, α-phenyl-tert-butyl-nitrone (PBN). J Neural Transm 104 (1997) 579-592
15. Heikkila R.E., Manzino L., Cabatt F.S., and Duvoisin R.S. Protection against the dopaminergic neurotoxicty of 1-methy-4-phenyl-1,2,3,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 311 (1984) 467-469
16. Heikkila R.E., Hess A., and Duvoisin R.C. Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. Science 224 (1984) 1451-1453
17. Hows M.E.P., Ashmeade T.E., Billinton A., Perren M.J., Austin A., Virley D.J., et al. High-performance liquid chromatography/tandem mass spectrometry assay for the determination of 1-methyl-4-phenyl pyridinium (MPP+) in brain tissue homogenates. J Neurosci Meth 137 (2004) 221-226
18. Hwang D.Y., Fleming S.M., Ardayfio P., Moran-Gates T., Kim H., Tarazi F.I., et al. 3,4-Dihydroxyphenylalanine reverses the motor deficits in pitx3-deficient aphakia mice: behavioural characterization of a novel genetic model of Parkinson's disease. J Neurosci 25 8 (2005) 2132-2137
19. Jackson-Lewis V., Jackowec M., Burke R.E., and Przedborski S. Time-course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurodegeneration 4 (1995) 257-269
20. Javoy-Agid F., and Agid Y. Is the mesocortical dopaminergic system involved in Parkinson's disease. Neurology 30 (1980) 1326-1330
21. Libertore G.T., Jackson-Lewis V., Vucosavik S., Mandir A.S., Vila M., McAuliffe W.G., et al. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Nat Med 5 (1999) 1403-1409
22. Mori A., Ohashi S., Nakai M., Moriizumi T., and Mitsumoto Y. Neural mechanisms underlying motor dysfunction as detected by the tail suspension test in MPTP-treated C57BL/6 mice. Neurosci Res 51 (2005) 265-274
23. Muralikrishnan D., Samantaray S., and Mohanakumar K.P. Deprenyl protects nigro-striatal neurons against MPTP-induced dopaminergic neurotoxicty. Synapse 50 (2003) 7-13
24. Nishi K., Kondo T., and Narabayashi H. Destruction of norepinephrine terminals in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice reduces locomotor activity induced by l-DOPA. Neurosci Lett 123 (1991) 244-247
25. Ogawa N., Hirose Y., Ohara S., Ono T., and Watnabe Y. A simple quantitative bradykinesia test in MPTP-treated mice. Res Commun Chem Pathol Pharmacol 50 (1985) 435-441
26. Pifl C.H., Schingnitz G., and Hornykiewicz O. The neurotoxin MPTP does not reproduce in the rhesus monkey the interregional pattern of striatal dopamine loss typical of human idiopathic Parkinson's disease. Neurosci Lett 92 (1988) 228-233
27. Przedborski S., and Vila M. The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model: a tool to explore the pathogenesis of Parkinson's disease. Ann NY Acad Sci 991 (2003) 189-198
28. Quinn L.P., Stean T.O., Chapman H., Brown M., Vidgeon-Hart M., Upton N., et al. Further validation of LABORAS using various dopaminergic manipulations in mice including MPTP-induced nigro-striatal degeneration. J Neurosci Meth 156 (2006) 218-227
29. Rascol O., Goetz C., Koller W., Poewe W., and Sampaio C. Treatment interventions for Parkinson's disease: an evidence based assessment. Lancet 359 (2002) 1589-1598
30. Ricaurte G.A., Irwin I., Forno L.S., DeLanny L.E., Langston E., and Langston J.W. Aging and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced degeneration of dopaminergic neurons in the substantia nigra. Brain Res 403 (1987) 43-51
31. Rousselet E., Joubert C., Callebert J., Parain K., Tremblay L., Orieux G., et al. Behavioural changes are not directly related to striatal monoamine levels, number of nigral neurons, or dose of parkinsonian toxin MPTP in mice. Neurobiol Dis 14 (2003) 218-228
32. Rozas G., Lopez-Martin E., Guerra M.J., and Labandeira-Garcia J.L. The overall rod performance test in the MPTP-treated mouse model of Parkinsonism. J Neurosci Meth 83 (1998) 165-175
33. Schroeder U., Kreutz M.R., Schroeder H., and Sabel B.A. Amphetamine induces hypermotility in MPTP-lesioned mice. Pharmacol Biochem Behav 56 (1997) 281-285
34. Sedelis M., Hofele K., Auburger G.W., Morgan S., Huston J.P., and Schwarting R.K.W. MPTP susceptibility in the mouse: behavioural, neurochemical, and histological analysis of gender and strain differences. Behav Genet 30 (2000) 171-182
35. Sonsalla P.K., and Heikkila R.E. The influence of dose and dosing interval on MPTP-induced dopaminergic neurotoxicity in mice. Eur J Pharmacol 129 (1986) 339-345
36. Sunstrom E., Stromberg I., Tsutsumi T., Olson L., and Jonsson G. Studies on the effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on central catecholamine neurons in C57BL/6 mice. Comparison with three other strains of mice. Brain Res 405 (1987) 26-38
37. Virely D.J., Beech J.S., Smart S.C., Williams S.C., Hodges H., and Hunter A.J. A temporal MRI assessment of neuropathology after transient middle cerebral artery occlusion in the rat: correlations with behaviour. J Cereb Blood Flow Metab 20 (2000) 563-582
38. Willis G.L., and Donnan G.A. Histochemical, biochemical and behavioural consequences of MPTP treatment in C-57 black mice. Brain Res 402 (1987) 269-274